SCHEMBL17079673

SCHEMBL17079673

CCc1ccc2c(c1CC)C(=O)OC21c2ccc(O)cc2Oc2cc(O)ccc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 10/20 0.55
MAPT P10636 3/20 0.55
HPGD P15428 2/20 0.55
MEN1 O00255 2/20 0.55
HTT P42858 2/20 0.55
KMT2A Q03164 2/20 0.55
CYP2C19 P33261 1/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
SMAD3 P84022 1/20 0.55
PRMT1 Q99873 1/20 0.55
ACE2 Q9BYF1 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 2/20 0.53
ALOX12 P18054 2/20 0.53
CYP2C9 P11712 1/20 0.53
ALOX15 P16050 1/20 0.53
BRCA1 P38398 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4941647 0.87 FTO (0.52) FTOMAPTHPGDMEN1HTT
SCHEMBL2314510 0.86 FTO (0.60) FTOMAPTHPGDMEN1HTT
SCHEMBL19206099 0.85 FTO (0.50) FTOMAPTHPGDMEN1HTT
SCHEMBL8196841 0.83 FTO (0.48) FTOMAPTHPGDMEN1HTT
SCHEMBL3788322 0.83 FTO (0.48) FTOMAPTHPGDMEN1HTT
SCHEMBL239423 0.81 HPGD (0.55) FTOMAPTHPGDMEN1HTT
SCHEMBL20438530 0.81 FTO (0.54) FTOMAPTHPGDMEN1HTT
SCHEMBL16010027 0.81 FTO (0.51) FTOMAPTHPGDMEN1HTT
SCHEMBL17956696 0.81 FTO (0.57) FTOMAPTHPGDMEN1HTT
SCHEMBL3485942 0.79 HPGD (0.50) FTOMAPTHPGDMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3116525-B1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS UNIV CALIFORNIA (US) 2021-06-23 EP disclosed
CN-106659796-B TCO conjugates and therapeutic agent delivery methods 加利福尼亚大学董事会 2021-04-30 CN disclosed
US-20210060188-A1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2021-03-04 US disclosed
US-10806807-B2 TCO conjugates and methods for delivery of therapeutic agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-10-20 US disclosed
US-10342882-B2 TCO conjugates and methods for delivery of therapeutic agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2019-07-09 US disclosed
US-20190111163-A1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-04-18 US disclosed
US-10130723-B2 TCO conjugates and methods for delivery of therapeutic agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-11-20 US disclosed
US-20170095580-A1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-04-06 US disclosed
US-20170087258-A1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2017-03-30 US disclosed
EP-3116525-A1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS The Regents of the University of California (US) 2017-01-18 EP disclosed
WO-2015139025-A1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2015-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342882-B2 TCO conjugates and methods for delivery of therapeutic agents FCGR2A, PAICS, CD47 FTO 4286/4885MAPT 2413/4885HPGD 3830/4885
US-20210060188-A1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS FCGR2A, PAICS, CD47 FTO 4286/4885MAPT 2413/4885HPGD 3830/4885
US-20170095580-A1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS FCGR2A, PAICS, CD47 FTO 4286/4885MAPT 2413/4885HPGD 3830/4885
US-20170087258-A1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS FCGR2A, PAICS, CD47 FTO 4286/4885MAPT 2413/4885HPGD 3830/4885
US-10806807-B2 TCO conjugates and methods for delivery of therapeutic agents FCGR2A, PAICS, CD47 FTO 4286/4885MAPT 2413/4885HPGD 3830/4885
US-10130723-B2 TCO conjugates and methods for delivery of therapeutic agents FCGR2A, PAICS, CD47 FTO 4286/4885MAPT 2413/4885HPGD 3830/4885
US-20190111163-A1 TCO CONJUGATES AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS FCGR2A, PAICS, CD47 FTO 4286/4885MAPT 2413/4885HPGD 3830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.